Alkermes (ALKS) Acquisitions (2011 - 2026)
Alkermes (ALKS) posted quarterly Acquisitions of $2.1 billion for Q1 2026, up 1109181.38% quarter-over-quarter from -$188000.0 in Q4 2011.
Alkermes (ALKS) Acquisitions (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Acquisitions for 2 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Acquisitions changed N/A year-over-year to $2.1 billion; the TTM figure through Jun 2026 stood at $2.1 billion (changed N/A YoY), while the FY2019 annual figure was $8.9 million, changed N/A from the prior year.
- Acquisitions advanced to $2.1 billion in Q1 2026 per ALKS's latest filing, from -$188000.0 in the prior quarter.
- Across five years, Acquisitions topped out at $2.1 billion in Q1 2026 and bottomed at $2.1 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.09 Bn |
| Dec 31, 2011 | -188,000.00 |